Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock LOS ANGELES...

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share.